BAYRHO-D MINI-DOSE Rx
Generic Name and Formulations:
Rho(D) immune globulin human 50mcg; for IM inj.
- Adjunctive Aripiprazole Lowers Prolactin Levels in Women With Psychosis
- Continuous Subcutaneous Insulin Infusion May Reduce Basal Hyperglycemia in T2D
- Sustained-Release Sodium Nitrite for Diabetic Neuropathic Pain Not Associated With Headaches
- Oral and Transdermal Estrogen Dose Equivalents
- Osteoporosis Treatments
- Beers List: Potentially Inappropriate Drugs for Elderly
Indications for BAYRHO-D MINI-DOSE:
Prevention of Rho(D) sensitization following termination of pregnancies up to 12 weeks gestation.
Each syringe (approx. 50mcg) prevents sensitization to 2.5mL of Rh positive red blood cells. Give IM up to 12 weeks' gestation, within 3 hours of an Rh incompatible delivery, miscarriage, or abortion.
Rho(D) positive patients. Pregnancy (Cat.C).
Live vaccines. Have epinephrine available.
Full Dose (single-dose syringes and vials)—1, 10; Mini-Dose (single-dose syringes)—10
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally